
Sarclisa Induction Boosts Progression-Free Survival in Transplant-Eligible Multiple Myeloma
Recent findings from the two-part, double-randomized GMMG-HD7 phase 3 study reveal that Sarclisa (isatuximab), combined with lenalidomide, bortezomib, and dexamethasone (RVd), significantly enhances progression-free survival (PFS) in newly diagnosed, transplant-eligible…












